Serotonin syndrome

1. History

• What serotonergic medications are currently prescribed (SSRIs, SNRIs, TCAs, MAOIs, triptans, opioids, etc.)?
• Any recent medication changes — new drug started, dose increased, or drug switched within the past 5 weeks? [1]
• Intentional overdose or accidental ingestion?
• Over-the-counter medications: dextromethorphan-containing cough medicines, St. John's Wort, tryptophan supplements? [1]
• Illicit drug use: MDMA ("ecstasy"), cocaine, amphetamines? [1]
• Time of symptom onset relative to medication change — 60% present within 6 hours, 74% within 24 hours [3]
• Symptom characterization: tremor, shivering, restlessness, diarrhea, muscle twitching, confusion
• Was a serotonergic drug recently discontinued (e.g., fluoxetine has a 5-week washout due to norfluoxetine)? [1]

2. Alarm Features

• Hyperthermia >41.1°C — hallmark of severe/life-threatening serotonin syndrome [1]
• Muscular rigidity (especially lower extremities) — may mask clonus and cloud diagnosis [1]
• Rapidly deteriorating mental status: agitated delirium → coma [1]
• Hemodynamic instability: severe hypertension deteriorating into shock [1]
• Seizures [5]
• Signs of end-organ damage: rhabdomyolysis, metabolic acidosis, DIC, renal failure [1]
• Any MAOI + serotonin reuptake inhibitor combination — highest risk for severe/fatal toxicity [1-2]

3. Medications

Causative agents (by mechanism): [1][6-7]

• Serotonin reuptake inhibitors: SSRIs (fluoxetine, sertraline, paroxetine, citalopram, escitalopram), SNRIs (venlafaxine, duloxetine, desvenlafaxine), TCAs (especially clomipramine), tramadol, meperidine, fentanyl, dextromethorphan, cyclobenzaprine
• MAO inhibitors: phenelzine, tranylcypromine, isocarboxazid, selegiline, rasagiline, linezolid, IV methylene blue [7-8]
• Serotonin releasers: MDMA, amphetamines, mirtazapine
• Serotonin precursors: tryptophan, 5-HTP
• Other: triptans, lithium, metoclopramide, ondansetron (controversial), St. John's Wort, bupropion (in overdose) [9-10]

Highest-risk combinations: MAOI + SSRI/SNRI, MAOI + meperidine, MAOI + dextromethorphan. [1][11] Concomitant SSRI-opioid use carries a strong pharmacovigilance signal (ROR 95.94). [12]

Contraindicated in treatment: Bromocriptine and dantrolene — associated with worsening hyperthermia and death in serotonin syndrome (these are NMS treatments, not SS treatments). [1] Avoid indirect sympathomimetics (e.g., dopamine) for hypotension in MAOI-related cases. [1]

Treatment medications:

• Cyproheptadine: 5-HT2A antagonist; initial dose 12 mg PO, then 2 mg q2h if symptoms persist; maintenance 8 mg q6h; max 32 mg/24h. Available only in oral form (can crush and give via NGT). Evidence for efficacy is limited to case reports. [1][13-14]
• Benzodiazepines: First-line for agitation control (e.g., diazepam, lorazepam) [1]
• Chlorpromazine: 50–100 mg IM for severe cases requiring parenteral therapy (avoid if hypotensive) [1]

4. Diet

• Avoid tyramine-rich foods if on MAOIs (aged cheeses, cured meats, fermented foods, draft beer) — can precipitate hypertensive crisis and compound serotonergic toxicity
• Avoid tryptophan-containing supplements [7]
• Aggressive IV fluid hydration is critical in acute management to prevent renal injury from rhabdomyolysis [1]

5. Review of Systems

• Neuro: Tremor, myoclonus, restlessness, confusion, agitation, seizures, headache
• GI: Diarrhea, nausea, vomiting, hyperactive bowel sounds (distinguishing feature from anticholinergic toxidrome) [1]
• Autonomic: Diaphoresis, shivering, flushing, palpitations
• Psych: Anxiety, hypervigilance, pressured speech, hallucinations, delirium
• MSK: Muscle twitching, stiffness (especially lower extremities)
• Ophthalmologic: Blurred vision (mydriasis)

6. Collateral History and Family History

• Confirm complete medication list from pharmacy records, family, EMS — patients may not recall all serotonergic agents
• Inquire about recent prescriber changes, multiple prescribers, or recent ED visits with new prescriptions
• Recreational drug use history from friends/family (MDMA, cocaine)
• Intentional self-harm assessment — overdose is a common precipitant [15]
• Family history of pharmacogenomic variants (CYP2D6 poor/intermediate metabolizers) may increase susceptibility [8]

7. Risk Factors

• Polypharmacy with multiple serotonergic agents — most common scenario [11]
• Recent initiation, dose increase, or switch of serotonergic medication [15]
• Intentional overdose of serotonergic drugs (moderate serotonin toxicity in ~14% of SSRI overdoses) [15]
• MAOI use (especially combined with SRIs — 50% develop at least moderate toxicity) [15]
• CYP2D6/CYP3A4 inhibitor co-administration (e.g., fluoxetine, paroxetine inhibiting CYP2D6) [1]
• Elderly patients — higher reporting odds ratios for serotonin syndrome [10][16]
• Perioperative setting — concomitant opioid + antidepressant use [12]

8. Differential Diagnosis

Key distinguishing pearl: Serotonin syndrome features hyperreflexia and clonus (especially lower extremities), hyperactive bowel sounds, diaphoresis with normal skin color, and rapid onset (<12 hours). NMS features bradyreflexia, lead-pipe rigidity, and slow onset (1–3 days). [1][3][17]

9. Past Medical History

• Psychiatric history: depression, anxiety, OCD, PTSD (all treated with serotonergic agents)
• Prior episodes of serotonin syndrome (recurrence risk with re-exposure)
• Chronic pain conditions (tramadol, fentanyl, meperidine use)
• Migraine (triptan use, especially with concurrent SSRI/SNRI) [19]
• Parkinson's disease (rasagiline, selegiline — MAO-B inhibitors can precipitate SS with SSRIs) [8]
• Infections requiring linezolid in patients on antidepressants [7]
• Hepatic/renal impairment (impaired drug metabolism)

10. Physical Exam

• Vitals: Tachycardia, hypertension (may progress to hypotension in severe cases), tachypnea, hyperthermia (>38°C moderate; >41.1°C severe/life-threatening) [1]
• Neuro: Clonus (inducible > spontaneous > ocular) — most diagnostically important finding; hyperreflexia (greater in lower extremities than upper); tremor; myoclonus; agitation [1][4]
• Eyes: Mydriasis, ocular clonus (slow continuous lateral eye movements) [1]
• Skin: Diaphoresis, normal skin color (vs. dry/flushed in anticholinergic) [1]
• Oral: Sialorrhea (vs. dry mucosa in anticholinergic) [1]
• Abdomen: Hyperactive bowel sounds (key distinguishing feature) [1]
• Musculoskeletal: Increased tone predominantly in lower extremities; in severe cases, generalized rigidity that may mask clonus [1]
• Mental status: Ranges from hypervigilance and pressured speech (moderate) to agitated delirium and coma (severe) [1]

11. Lab Studies

There is no confirmatory laboratory test for serotonin syndrome — it is a clinical diagnosis. [1]

• CBC: Leukocytosis may be present but nonspecific
• BMP/CMP: Evaluate for metabolic acidosis, renal function (creatinine elevation in rhabdomyolysis), electrolytes
• CK (creatine kinase): Elevated in rhabdomyolysis from sustained muscle hyperactivity [1][20]
• LFTs: Elevated aminotransferases in severe cases [1]
• Coagulation studies: PT/INR, fibrinogen, D-dimer — DIC can occur in severe cases [1]
• Lactate: Elevated from muscle hyperactivity and metabolic acidosis
• Urinalysis: Myoglobinuria
• TSH: Rule out thyroid storm
• Blood/urine toxicology screen: Identify co-ingestants
• Serum iron: May help distinguish from NMS (low in NMS) [21]

12. Imaging

• No specific imaging is diagnostic for serotonin syndrome
• CT head: Consider if altered mental status to rule out intracranial pathology (hemorrhage, mass)
• Chest X-ray: If concern for aspiration (agitated/obtunded patients) or respiratory failure
• Imaging is generally unnecessary if clinical presentation and medication history are consistent with serotonin syndrome

13. Special Tests

• Hunter Serotonin Toxicity Criteria — preferred diagnostic decision rules (sensitivity 84%, specificity 97%). Requires a serotonergic agent AND one of: [4]
  • Spontaneous clonus
  • Inducible clonus + agitation or diaphoresis
  • Ocular clonus + agitation or diaphoresis
  • Tremor + hyperreflexia
  • Hypertonia + temperature >38°C + ocular or inducible clonus [4][19][22]
• Sternbach Criteria — older, less specific; requires ≥3 of 10 features (agitation, tremor, myoclonus, hyperreflexia, diaphoresis, shivering, diarrhea, incoordination, fever) [19]
• Poison control consultation — recommended for complex polypharmacy cases
• Pharmacogenomic testing (CYP2D6) — consider in recurrent or unexpectedly severe cases on standard doses [8]

14. ECG

• Sinus tachycardia — most common finding [1]
• Evaluate for QTc prolongation — many serotonergic drugs (especially citalopram, escitalopram, TCAs) prolong QT
• Rule out wide-complex arrhythmias in TCA co-ingestion (sodium channel blockade)
• Continuous cardiac monitoring recommended for moderate-to-severe cases

15. Assessment

Serotonin syndrome exists on a severity spectrum: [1-2]

• Mild: Tremor, hyperreflexia, tachycardia, diaphoresis, mydriasis — afebrile. May be overlooked or attributed to anxiety.
• Moderate: Above features plus hyperthermia (up to 40°C), clonus (especially lower extremities), ocular clonus, agitation, hyperactive bowel sounds, hypertension
• Severe: Temperature >41.1°C, muscular rigidity (may mask clonus), agitated delirium → coma, hemodynamic instability → shock, rhabdomyolysis, metabolic acidosis, DIC, seizures, multi-organ failure

Most cases are mild and self-limited with drug discontinuation. [22-23] Severe cases are most commonly associated with MAOI + serotonin reuptake inhibitor combinations. [2] Complications of poorly treated hyperthermia drive mortality (rhabdomyolysis, renal failure, DIC). [1]

16. Treatment Plan

Initial stabilization (all severities):

• Discontinue all serotonergic agents immediately [1]
• ABCs, IV access, continuous monitoring
• Avoid physical restraints — isometric contractions worsen lactic acidosis and hyperthermia [1]

Mild cases:

• Supportive care + observation
• Benzodiazepines for agitation/tremor (e.g., diazepam 5–10 mg IV, lorazepam 1–2 mg IV) [1]
• IV fluids

Moderate cases:

• Aggressive correction of cardiorespiratory and thermal abnormalities
• Cyproheptadine: 12 mg PO initial dose → 2 mg PO q2h PRN → maintenance 8 mg PO q6h (max 32 mg/24h) [1]
• Active cooling measures
• Benzodiazepines for agitation

Severe cases (temp >41.1°C):

• Immediate sedation, neuromuscular paralysis (non-depolarizing agents — avoid succinylcholine), and endotracheal intubation [1]
• Aggressive cooling (evaporative cooling, ice packs, cooled IV fluids)
• Cyproheptadine via NGT
• Chlorpromazine 50–100 mg IM if parenteral 5-HT2A antagonism needed (avoid if hypotensive) [1]
• Treat hypotension with direct-acting vasopressors (norepinephrine, phenylephrine) — avoid indirect agents like dopamine in MAOI-related cases [1]
• Treat hypertension/tachycardia with short-acting agents (nitroprusside, esmolol) [1]
• Do NOT use: antipyretics (ineffective — hyperthermia is from muscle activity, not hypothalamic reset), bromocriptine, dantrolene [1]

17. Disposition

• Discharge: Mild cases (tremor, hyperreflexia, no fever) that resolve after observation (typically 6–8 hours), with offending agent discontinued and no ongoing serotonergic exposure [1][22]
• Observation/floor admission: Moderate cases requiring active treatment, hemodynamically stable but with persistent symptoms
• ICU admission: Severe cases with hyperthermia >40°C, hemodynamic instability, altered mental status, need for intubation/paralysis, evidence of rhabdomyolysis or end-organ damage [14][22]
• Toxicology/Poison Control consultation: Recommended for all moderate-to-severe cases and complex polypharmacy ingestions
• Psychiatry consultation: If intentional overdose or self-harm

18. Follow Up / Return Precautions

• Most cases resolve within 24 hours of drug discontinuation, but symptoms may persist longer with drugs that have long half-lives (e.g., fluoxetine → norfluoxetine, t½ ~1–2 weeks) [1]
• Return immediately for: recurrence of tremor/muscle twitching, fever, confusion, agitation, rapid heart rate, profuse sweating
• Outpatient follow-up with prescribing physician within 24–72 hours to review medication regimen and plan safe alternatives
• Educate patients: serotonin syndrome is predictable and preventable — it is a pharmacologic adverse reaction, not idiosyncratic [23]
• Ensure medication reconciliation across all prescribers to avoid inadvertent serotonergic polypharmacy
• If restarting antidepressant therapy, allow adequate washout (2 weeks for most agents; 5 weeks for fluoxetine before starting an MAOI) [1]
• Consider pharmacogenomic testing if severe reaction occurred on standard doses [8]